Metoclopramide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Metoclopramide: From Gastroesophageal Reflux Disease to Gastric Ulcer
One-Sentence Summary
Metoclopramide is a prokinetic and antiemetic drug, originally used for gastroesophageal reflux disease and reflux esophagitis. The TxGNN model predicts it may be effective for gastric ulcer, but the supporting evidence is thin: 1 clinical trial (a procedural, endoscopy-premedication study) and 20 publications, mostly older reviews on motility disorders.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gastroesophageal reflux disease; esophagitis; peptic esophagitis (from the knowledge graph, as the Singapore licence records contain no indication text) |
| Predicted New Indication | Gastric ulcer |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L3 (observational/review-level evidence only; no completed Phase 3 or Phase 2/3 RCT for ulcer treatment) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, metoclopramide is a dopamine D2 antagonist and 5-HT4 agonist that increases upper gastrointestinal motility, raises lower oesophageal sphincter tone and speeds gastric emptying. This is how it helps in reflux disease.
Gastric ulcer is a neighbouring upper-GI condition. Delayed gastric emptying and duodenogastric (bile) reflux often accompany it, so a motility-based benefit is plausible. However, metoclopramide does not suppress acid or promote mucosal healing. At best it offers symptomatic support alongside standard ulcer therapy, not direct ulcer treatment. The high TxGNN score likely reflects network proximity between reflux and ulcer diseases rather than demonstrated efficacy.
Other predictions follow the same pattern. Gastroduodenitis (99.90%), peptic ulcer disease (99.85%) and gastrojejunal ulcer (99.78%) are supported mainly by indirect motility literature. Peptic ulcer perforation and duodenal obstruction raise safety concerns, since prokinetics are contraindicated in perforation and mechanical obstruction. Achlorhydria and cascade stomach have no meaningful mechanistic link.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05746377 | Phase 4 | Unknown | 60 | Double-blind trial of metoclopramide premedication in upper GI bleeding, testing whether it reduces repeat endoscopy, interventional radiology or surgery and improves visualisation. This is a procedural use, not ulcer healing. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 786607 | 1976 | Review | Drugs | Review of metoclopramide's pharmacology and uses, including easing emergency endoscopy in upper GI haemorrhage |
| 19445547 | 2009 | Systematic review | Paediatric Drugs | Evidence-based review of drug treatment for paediatric gastro-oesophageal reflux |
| 12825960 | 2003 | Review | Drugs | Diabetic gastroparesis, where treatment options are limited |
| 11879596 | 2002 | Review | Curr Treat Options Gastroenterol | Functional (non-ulcer) dyspepsia and delayed gastric emptying |
| 6782467 | 1981 | Randomised crossover study | MMW Munch Med Wochenschr | In 12 healthy men, metoclopramide and domperidone did not significantly change serum gastrin or gastric acid secretion |
| 579607 | 1978 | Symposium review | Can J Surg | Medical treatment of peptic ulcer, noting metoclopramide hastens gastric emptying |
| 8095331 | 1993 | Review | Postgrad Med | Strategies for refractory peptic lesions and reflux oesophagitis |
| 8686797 | 1996 | Review | Am J Surg | Delayed gastric emptying after gastric surgery, often for peptic ulcer |
| 7017896 | 1981 | Review | Scand J Gastroenterol Suppl | Treatment limits in duodenogastric reflux; some drugs act by speeding gastric emptying |
| 3970596 | 1985 | Case series | Ann Surg | 42 patients with spontaneous enterogastric reflux gastritis and oesophagitis |
For the other predicted indications, two recent RCT-type publications (PMIDs 38059896 and 42259699) evaluate metoclopramide for gastric visualisation in acute upper GI bleeding. Both concern a procedural use, not treatment of ulcer or gastroduodenitis. A rat study (PMID 2730234, 1989) reported ulcer-protective and antisecretory effects of metoclopramide in aspirin-induced and pylorus-ligated models. This is preclinical only.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN06638P | PULIN INJECTION 10 mg/2 ml | Injection | Not stated in the data |
| SIN02804P | METOCLOPRAMIDE TABLET 10 mg | Tablet | Not stated in the data |
| SIN03349P | METOCLOPRAMIDE SYRUP 5 mg/5 ml | Syrup | Not stated in the data |
| SIN05202P | METOCLOPRAMIDE INJECTION BP 5 mg/ml | Injection | Not stated in the data |
| SIN10581P | PULIN FILM-COATED TABLET 10 mg | Film-coated tablet | Not stated in the data |
A sixth licence (SIN03350P, SW METOCLOPRAMIDE TABLET 10 mg) is also valid. All six are single-ingredient products.
Safety Considerations
- Contraindications flagged by the knowledge graph (not taken from label text): hypertension, epilepsy, phaeochromocytoma and paraganglioma, porphyria, active peptic ulcer disease, Parkinson disease and parkinsonian disorders, tardive dyskinesia, torsion dystonia, neuroleptic malignant syndrome, cirrhosis of liver, impaired renal function, anxiety and related disorders, and several others. The listing of active peptic ulcer disease is directly relevant to this repurposing question and needs careful review.
- Mechanical obstruction and perforation: prokinetics should not be used in these settings, which makes the peptic ulcer perforation and duodenal obstruction predictions unsuitable to pursue.
- Drug interactions: 100 interactions were found. The main ones are:
- Major: tramadol, amisulpride.
- Moderate: opioids (fentanyl, alfentanil, codeine, dihydrocodeine), sedating antihistamines (chlorpheniramine, cetirizine), alprazolam, amitriptyline, amobarbital, amantadine, abiraterone, ethanol, and others.
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but the only registered trial tests endoscopy premedication, not ulcer treatment, and the literature is mostly older reviews of motility disorders. Metoclopramide has no acid-suppressive or mucosal-healing action, and the knowledge graph lists active peptic ulcer disease as a contraindication. The evidence supports at most adjunctive symptom relief.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (a blocking gap for safety screening)
- Mechanism of action data (for example from DrugBank)
- Clarification of the contraindication on active peptic ulcer disease
- A clinical question restricted to a defined subpopulation (for example ulcer with delayed gastric emptying), supported by controlled trial data
- A clear plan for how metoclopramide would fit alongside standard acid-suppressive therapy
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.